Figure 6

Effect of treatment with roflumilast on cigarette smoke-induced lung inflammation. Mice were treated with oral vehicle only or with oral roflumilast (5 mg/kg/day) and exposed to cigarette smoke for one week, as per protocol design described in Figure 3A. Neutrophil counts (A), KC (B) and pro-MMP-9 levels (C) were measured in BAL. Results are expressed as percentage of neutrophils, KC or pro-MMP-9 levels in vehicle-treated and smoke-exposed animals (± SEM). ***: p < 0.001; t-test versus vehicle-treated without smoke exposure (compilation of 4 independent experiments, n = 12–21 mice per group for neutrophils and KC, and 3–6 per group for pro-MMP-9).